A Phase I Study of LY2523355 in Patients With Advanced Cancer
This study is a multi-center, non-randomized, open label, dose-escalation, Phase 1 study of
intravenous LY2523355 in patients with advanced and/or metastatic cancer (including
Non-Hodgkin's Lymphoma) for whom no treatment of higher priority exists.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Recommended dose for Phase 2 Studies
Baseline to study completion
Yes
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
United States: Food and Drug Administration
11618
NCT01214629
July 2007
May 2012
Name | Location |
---|---|
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dunmore, Pennsylvania 18512 |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Albuquerque, New Mexico 87106 |